| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Diabetes > Diabetes - What Is Type 1 Diabetes? |
|
Advice Pool - Diabetes - What Is Type 1 Diabetes?
Type 1 Diabetes is an auto immune disease that destroys the insulin producing cell According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product s of the pancreas. Type 1 Diabetes used to be called juvenile diabetes because it ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in sually struck people under 20. In type 1 diabetes, the beta cells of the pancreas lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. roduce little or no insulin, the hormone that allows glucose to enter body cells. here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe nce glucose enters a cell, it is used as fuel. Type 1 Diabetes is largely inherit d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro d. Without adequate insulin, glucose builds up in the bloodstream instead of goin ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc into the cells. The body is unable to use this glucose for energy despite high le easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi els in the bloodstream, leading to increased hunger. In addition, the high levels nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically of glucose in the blood causes the patient to urinate more, which in turn causes e and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ cessive thirst. Within 5 to 10 years after diagnosis, the insulin-producing beta c ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi lls of the pancreas are completely destroyed, and no more insulin is produced maki ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ng people with type 1 insulin dependent. Type 1 diabetes can occur at any age, bu dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod it usually starts in people younger than 30. Symptoms are usually severe and occu cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin rapidly. The exact cause of type 1 diabetes is not known. Type 1 diabetes accoun tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen s for 3% of all new cases of diabetes each year. There is 1 new case per every 7,0 t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel 0 children per year. New cases are less common among adults older than 20. The re ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ult is Type 1 Diabetics are hungry all the time trying to make up for the shortfal y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products of insulin. Amazingly though since the body cannot process the nutrients weight l . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ss is symptomatic along with extreme thirst and excessive urination. The kidneys t elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip y to process the excess glucose to balance things out. Weakness is another symptom tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Secrets to Help You Find Your Unclaimed Money Mortgage Rates Increase Due to Inflation Concerns
|